08
November

08:00 AM EST

Oncology

Strategy Meeting East Coast USA 2022

Exploring Promising Areas in Oncology Research Aimed to Expand Our Knowledge Base, Address Unmet Medical Needs and Improve Overall Clinical Success

Le Meridien Cambridge Boston

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Oncology Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Oncology professionals from across the East Coast, in Boston MA, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Meet Our 2022 Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. Whilst we?re busy connecting with the best industry experts, take a look at facilitators at our Strategy Meeting taking place in May

Claudia Hesselmann, PhD

Co-founder & CEO ARENSIA

Tatiana Eidus

Director, Corporate Development North America Arensia

Déborah Heintze

Co-founder and Chief Marketing Officer Lunaphore Technologies

Dr. Antonio Sorrentino

Head of Translational Strategy Lunaphore Technologies

Andrew Jackson

U.S. Commercial Director Sengenics

Katy McGirr

Director of Global Marketing Sengenics

Laurent Audoly

Founder, CEO, Chairman of the Board Parthenon Therapeutics

Vivian Choi

Head of Global Gene Therapy Research Takeda

Tirtha Chakraborty

Chief Scientific Officer Vor Biopharma

Sashka Dimitrievska

Global Therapeutic Area Head Oncology Clinical Insights AstraZeneca

Gregory Fiore

Chief Executive Exacis Biotherapeutics

Marco Gottardis

Vice President of Oncology Innovation Janssen Pharmaceutical Companies of Johnson & Johnson

Vijay Kasturi

Vice President, Clinical Development/ Medical Affairs AVEO Oncology

An accomplished hematologist-oncologist and researcher, Dr. Vijay Kasturi oversees the medical affairs team at Aveo Oncology. For more than 25 years Vijay has built a stellar career establishing and executing global and regional strategies that have brought innovative new treatment options to patients in hematology and oncology.
Prior to joining Aveo, Vijay was SVP of Scientific Affairs at FerGene, and led both Medical Affairs and Clinical Development.  He has also led U.S. Medical Affairs, Oncology for EMD Serono where he had broad leadership responsibilities, including external stakeholder  management, evidence generation, medical education and publication strategy. During his time with EMD Serono, Vijay also developed and managed the global medical strategy and launch plan for the company’s anti-PD-L1 agent (avelumab), including indications in Merkel cell, urothelial, and kidney cancer.
Earlier in this career, Vijay served as an Assistant Professor of Medicine, Division of Hematology-Oncology  at the University of Massachusetts Medical School and was the program leader for genitourinary oncology at UMass Memorial Cancer Center. He trained in Hematology-Oncology at the National Cancer Institute  and worked as an investigator and physician at the National Cancer Institute and at Dartmouth Hitchcock  Medical Center.
He has authored numerous publications and has been the recipient of numerous awards for his work in   medicine.

Karuppiah Kannan

Executive Director – Global Program Leader Takeda

Karuppiah Kannan is an Executive Director in the department of Drug Development Management at <a href="https://www.takeda.com/">Takeda Pharmaceuticals</a>, where he has been working for the past 8+ years. Prior to that, Kannan was at AVEO Pharmaceuticals, joined as one of the first five employees of the company, helped build the company to be a 200 employee company by the time he left, leading various efforts in Discovery and Translational research for oncology drugs. He is a founder/treasurer of Boston Pharmaceutical and Biosciences Society, a non-profit organization that fosters education and training among early career scientists in the greater Boston area. Through his school days he has fought against female infanticide, dowry system and gender inequality specifically fighting for education for women which were common problems in the region where he grew up. He was an ardent supporter of women in STEM through active participation and volunteering in Diversity & Inclusion programs at Takeda, DIGITs program, Cambridge Science Fair, MSSEF etc. He is also a founding biking Team Captain for Team Takeda, helping team members train and ride Pan Mass Challenge and raised ~$290K in 7 years to support cancer research.

Johanna Kaufmann, PhD

Executive Vice President Oncology Codagenix Inc.

Geoffrey Hodge

Chief Executive Officer Sotio

Jeffrey Humphrey

Member of Board of Directors Constellation Pharmaceuticals

Dr. Jeff Humphrey is currently Chief Medical Officer of Constellation Pharmaceuticals overseeing development of a pipeline of drugs that modify epigenetic regulation of gene expression. Previously at Kyowa Kirin as Chief Development Officer, he built US and EU research capabilities and guided development of burosumab, mogamulizumab, and istradefylline to approvals and US/EU launches (Poteligeo®, Nourianz®, Crysvita®). Dr. Humphrey began industry clinical research at Bristol-Myers Squibb and subsequently served in management positions for early and late drug development and medical affairs at Pfizer, Bayer, and Bristol Myers Squibb, participating in development of novel oncology drugs in all phases, from pre-IND to post-launch (Nexavar®, Erbitux®, Sprycel®, Yervoy®). Dr. Humphrey is a graduate of Harvard College and CWRU School of Medicine, and completed medical residency at the Johns Hopkins Hospital and post-doctoral fellowships in human genetics and medical oncology at the US National Institutes of Health and National Cancer Institute, where he was board-certified in oncology.

Mr. Punit Upadhyaya

Director Curie Therapeutics

Oscar Segurado

Chief Medical Officer ASC Therapeutics

Oscar Segurado is an executive veteran of the biopharmaceutical industry with extensive global leadership experience in translational science, clinical development and global medical affairs. C-suite executive and industry leader providing in-depth expertise for pre-clinical and clinical study strategy, planning, execution and monitoring, regulatory interactions, investor relations, fundraising, M&A and IPO process and deliverables. Chief Medical Officer for ASC Therapeutics, former CMO for Symvivo, Myriad Genetics and CellMax Life, Vice President for Becton Dickinson and Global Medical Head for Abbott/AbbVie (Humira). Author and co-author of over 100 peer-reviewed publications, including Nature, Lancet and Journal of Experimental Medicine, books and medical articles and member of several scientific and medical societies. Holding a tenured Professorship of Immunology at the University of Leon, Spain. Received PhD from the University of Wuerzburg, Germany and MD from the University of Salamanca, Spain.

David Sherris

CEO Attivare Therapeutics

Session – Next Generation OV and New Combinational Approaches for Treatment of Solid Tumors 
Dr. Sherris has over 30 years’ experience in translational medicine involving basic research, pharmaceutics and diagnostics.  Dr. Sherris has been a successful serial entrepreneur developing biotechnology companies from the ground up, devising corporate strategy, enacting programs and carrying companies through funding and acquisition.  Dr. Sherris prides himself as a “roll up your sleeves” CEO, entrepreneur, business development officer, drug developer and scientist, not simply a delegator. Dr. Sherris has worked with venture capital companies where he has both advised and raised finances for biotech companies.  Dr. Sherris has been employed by pharmaceutical and biotechnology companies to manage external (academic groups and contract research organizations) and internal (directly manage, augment and expand internal scientific programs) research and development. Dr. Sherris has been a frequently invited guest speaker at biopharmaceutical business and scientific conferences, a published author and holder of patents in a wide range of therapeutic areas including oncology, ophthalmology, dermatology, neurology, gene therapy and infectious disease.  Dr. Sherris has held positions of increasing responsibility in public and private companies. Dr. Sherris has developed drugs from the bench to the clinic, partnered technologies to pharmaceutical companies and raised capital for companies at the triple digit million dollar levels.

Reshma Singh

Director, Translational Medicine Takeda

George Tetz

Chief Executive Officer CLS Therapeutics

First name	Last name	Job title	Company name	Photo URL	Bio Position
Claudia	Hesselmann, PhD	Co-founder & CEO	ARENSIA	https://proventainternational.com/wp-content/uploads/2020/01/Claudia-Hesselmann-Arensia-Headshot-e1584469734743.png	Claudia Hesselmann, PhD, a chemist by training, with a PhD in molecular biology. Claudia has twenty years of expertise in the early phases of drug development. Her experience includes co-founding and holding management positions in various CROs. Her extensive background and social acumen, along with her first-hand knowledge of the industry, led Claudia to co-found ARENSIA Exploratory Medicine in Düsseldorf, Germany. Her primary aim is the contribution of innovative approaches to bring about substantial acceleration to the drug development process and enable more agile patient access to novel therapeutics.
Tatiana	Eidus	Director, Corporate Development North America	Arensia	https://proventainternational.com/wp-content/uploads/2020/05/Tatiana-Eidus.jpg	Tatiana Eidus received her Master’s Degree in Biophysics from Moscow State University. Entering the industry more than a decade ago, Tatiana has accumulated wide expertise in all the operational aspects of initiating and managing Phase I-III trials across Europe and US. Prior to joining ARENSIA Exploratory Medicine, Tatiana worked for GSK and Merck. Primarily focused on early-stage exploratory programs, she conducted trials in various disease areas. In her current role as Director Corporate Development, Tatiana supports ARENSIA’s partners in the US, supervising cross-functional coordination throughout study planning, start-up and execution.
Déborah	Heintze	Co-founder and Chief Marketing Officer	Lunaphore Technologies	https://proventainternational.com/wp-content/uploads/2022/09/Deborah-Heintze.jpg
Dr.	Antonio Sorrentino	Head of Translational Strategy	Lunaphore Technologies	https://proventainternational.com/wp-content/uploads/2022/09/Antonio-Sorrentino.jpg
Andrew	Jackson	U.S. Commercial Director	Sengenics	https://proventainternational.com/wp-content/uploads/2022/09/Andrew-Jackson.jpg
Katy	McGirr	Director of Global Marketing	Sengenics	https://proventainternational.com/wp-content/uploads/2022/09/Katy-McGirr.jpg
Laurent	Audoly	Founder, CEO, Chairman of the Board	Parthenon Therapeutics	https://proventainternational.com/wp-content/uploads/2022/08/Laurent-Audoly.jpg	Laurent is a serial biotech entrepreneur and senior executive in the industry. He has led and/or contributed to the identification and development of seven novel medicines (Xeljanz®, Hemangiol®, Javlor®, Renflexis®, Brenzys®, Ontruzant®, Hadlima® – biologics and small molecules) addressing unmet medical need across multiple disease areas that generate > $2B in annual sales. Laurent has also led business and R&D functions in both pharma and biotech (US and EU), including CEO of Kymera Therapeutics, head of R&D with Pierre Fabre Pharmaceuticals, and positions of increasing leadership responsibilities on the business and science fronts at Pfizer, Merck, MedImmune, and Pieris contributing to the advancement of 21 drug candidates into clinical development across multiple disease areas and modalities.
Vivian	Choi	Head of Global Gene Therapy Research	Takeda	https://proventainternational.com/wp-content/uploads/2022/07/Vivian-Choi.jpg
Tirtha	Chakraborty	Chief Scientific Officer	Vor Biopharma	https://proventainternational.com/wp-content/uploads/2022/09/Tirtha-Chakraborty.jpg
Sashka	Dimitrievska	Global Therapeutic Area Head Oncology Clinical Insights	AstraZeneca	https://proventainternational.com/wp-content/uploads/2021/02/Sashka-Dimitrievska.jpeg	Sashka leads the Global AstraZeneca Oncology Information Practice (IP) department focused on generating informed decisions in late stage drug development across the oncology portfolio. Prior to joining AstraZeneca in 2017, Sashka worked in Alexion Pharmaceuticals Strategy & Intelligence, followed by a role in Alexion US Marketing. She holds a PhD in Biomedical Engineering and an MBA training from Yale University.
Gregory	Fiore	Chief Executive	Exacis Biotherapeutics	https://proventainternational.com/wp-content/uploads/2022/06/Gregory-Fiore.jpg
Marco	Gottardis	Vice President of Oncology Innovation	Janssen Pharmaceutical Companies of Johnson & Johnson	https://proventainternational.com/wp-content/uploads/2022/10/Janssen.jpg
Vijay	Kasturi	Vice President, Clinical Development/ Medical Affairs	AVEO Oncology	https://proventainternational.com/wp-content/uploads/2021/09/Vijay-Kasturi-scaled-e1631527003583.jpg	An accomplished hematologist-oncologist and researcher, Dr. Vijay Kasturi oversees the medical affairs team at Aveo Oncology. For more than 25 years Vijay has built a stellar career establishing and executing global and regional strategies that have brought innovative new treatment options to patients in hematology and oncology. Prior to joining Aveo, Vijay was SVP of Scientific Affairs at FerGene, and led both Medical Affairs and Clinical Development. He has also led U.S. Medical Affairs, Oncology for EMD Serono where he had broad leadership responsibilities, including external stakeholder management, evidence generation, medical education and publication strategy. During his time with EMD Serono, Vijay also developed and managed the global medical strategy and launch plan for the company’s anti-PD-L1 agent (avelumab), including indications in Merkel cell, urothelial, and kidney cancer. Earlier in this career, Vijay served as an Assistant Professor of Medicine, Division of Hematology-Oncology at the University of Massachusetts Medical School and was the program leader for genitourinary oncology at UMass Memorial Cancer Center. He trained in Hematology-Oncology at the National Cancer Institute and worked as an investigator and physician at the National Cancer Institute and at Dartmouth Hitchcock Medical Center. He has authored numerous publications and has been the recipient of numerous awards for his work in medicine.
Karuppiah	Kannan	Executive Director – Global Program Leader	Takeda	https://proventainternational.com/wp-content/uploads/2022/09/Karuppiah-Kannan.jpg	Karuppiah Kannan is an Executive Director in the department of Drug Development Management at Takeda Pharmaceuticals, where he has been working for the past 8+ years. Prior to that, Kannan was at AVEO Pharmaceuticals, joined as one of the first five employees of the company, helped build the company to be a 200 employee company by the time he left, leading various efforts in Discovery and Translational research for oncology drugs. He is a founder/treasurer of Boston Pharmaceutical and Biosciences Society, a non-profit organization that fosters education and training among early career scientists in the greater Boston area. Through his school days he has fought against female infanticide, dowry system and gender inequality specifically fighting for education for women which were common problems in the region where he grew up. He was an ardent supporter of women in STEM through active participation and volunteering in Diversity & Inclusion programs at Takeda, DIGITs program, Cambridge Science Fair, MSSEF etc. He is also a founding biking Team Captain for Team Takeda, helping team members train and ride Pan Mass Challenge and raised ~$290K in 7 years to support cancer research.
Johanna	Kaufmann, PhD	Executive Vice President Oncology	Codagenix Inc.	https://proventainternational.com/wp-content/uploads/2022/06/Johanna-Kaufmann.jpg	Dr. Kaufmann is a scientific and strategic leader in immuno-oncology with broad expertise across preclinical and translational drug development. Before joining Codagenix, she was a Scientific Director at GSK, leading an immune biology group and supporting progression of multiple portfolio assets as part of the immuno-oncology senior leadership team. She previously led mechanisms of action studies for immuno-oncology assets at TESARO and headed three preclinical herpes virus vaccine programs at Genocea Biosciences. Dr. Kaufmann earned a MS in Molecular Medicine from Friedrich-Alexander University in Erlangen, Germany, and a PhD in Cancer Virology from the German Cancer Research Center (DKFZ) and Heidelberg University, Germany.
Geoffrey	Hodge	Chief Executive Officer	Sotio	https://proventainternational.com/wp-content/uploads/2022/08/Geoffrey-Hodge.jpg
Jeffrey	Humphrey	Member of Board of Directors	Constellation Pharmaceuticals	https://proventainternational.com/wp-content/uploads/2021/02/Jeffrey-Humphrey-1.jpg	Dr. Jeff Humphrey is currently Chief Medical Officer of Constellation Pharmaceuticals overseeing development of a pipeline of drugs that modify epigenetic regulation of gene expression. Previously at Kyowa Kirin as Chief Development Officer, he built US and EU research capabilities and guided development of burosumab, mogamulizumab, and istradefylline to approvals and US/EU launches (Poteligeo®, Nourianz®, Crysvita®). Dr. Humphrey began industry clinical research at Bristol-Myers Squibb and subsequently served in management positions for early and late drug development and medical affairs at Pfizer, Bayer, and Bristol Myers Squibb, participating in development of novel oncology drugs in all phases, from pre-IND to post-launch (Nexavar®, Erbitux®, Sprycel®, Yervoy®). Dr. Humphrey is a graduate of Harvard College and CWRU School of Medicine, and completed medical residency at the Johns Hopkins Hospital and post-doctoral fellowships in human genetics and medical oncology at the US National Institutes of Health and National Cancer Institute, where he was board-certified in oncology.
Mr.	Punit Upadhyaya	Director	Curie Therapeutics	https://proventainternational.com/wp-content/uploads/2022/11/Punit-Upadhyaya-New.jpg
Oscar	Segurado	Chief Medical Officer	ASC Therapeutics	https://proventainternational.com/wp-content/uploads/2021/09/Photo_Oscar-Segurado_F0-e1631533577811.jpeg	Oscar Segurado is an executive veteran of the biopharmaceutical industry with extensive global leadership experience in translational science, clinical development and global medical affairs. C-suite executive and industry leader providing in-depth expertise for pre-clinical and clinical study strategy, planning, execution and monitoring, regulatory interactions, investor relations, fundraising, M&A and IPO process and deliverables. Chief Medical Officer for ASC Therapeutics, former CMO for Symvivo, Myriad Genetics and CellMax Life, Vice President for Becton Dickinson and Global Medical Head for Abbott/AbbVie (Humira). Author and co-author of over 100 peer-reviewed publications, including Nature, Lancet and Journal of Experimental Medicine, books and medical articles and member of several scientific and medical societies. Holding a tenured Professorship of Immunology at the University of Leon, Spain. Received PhD from the University of Wuerzburg, Germany and MD from the University of Salamanca, Spain.
David	Sherris	CEO	Attivare Therapeutics	https://proventainternational.com/wp-content/uploads/2020/01/David-Sherris-1.jpg	Session – Next Generation OV and New Combinational Approaches for Treatment of Solid Tumors Dr. Sherris has over 30 years’ experience in translational medicine involving basic research, pharmaceutics and diagnostics. Dr. Sherris has been a successful serial entrepreneur developing biotechnology companies from the ground up, devising corporate strategy, enacting programs and carrying companies through funding and acquisition. Dr. Sherris prides himself as a “roll up your sleeves” CEO, entrepreneur, business development officer, drug developer and scientist, not simply a delegator. Dr. Sherris has worked with venture capital companies where he has both advised and raised finances for biotech companies. Dr. Sherris has been employed by pharmaceutical and biotechnology companies to manage external (academic groups and contract research organizations) and internal (directly manage, augment and expand internal scientific programs) research and development. Dr. Sherris has been a frequently invited guest speaker at biopharmaceutical business and scientific conferences, a published author and holder of patents in a wide range of therapeutic areas including oncology, ophthalmology, dermatology, neurology, gene therapy and infectious disease. Dr. Sherris has held positions of increasing responsibility in public and private companies. Dr. Sherris has developed drugs from the bench to the clinic, partnered technologies to pharmaceutical companies and raised capital for companies at the triple digit million dollar levels.
Reshma	Singh	Director, Translational Medicine	Takeda	https://proventainternational.com/wp-content/uploads/2022/10/Reshma-Singh.jpg
George	Tetz	Chief Executive Officer	CLS Therapeutics	https://proventainternational.com/wp-content/uploads/2022/06/George-Tetz.jpg	Dr. Tetz’s research is a pioneer in uncovering the role of extracellular nucleic acids as a new group of previously overlooked therapeutic targets. His discoveries paved a way for the therapy of devastating pathologies such as therapy-resistant cancers, stroke, graft- versus host disease and neurodegenerative conditions. Dr. Tetz has over 19 years of experience in strategic management, research, and commercialization in life science. He is a Co-founder and CEO of CLS Therapeutics which is developing novel drugs based on a proprietary “CLS-DEnz” platform utilizing a cell-free DNA as a novel therapeutic target.

Claudia Hesselmann, PhD, Tatiana Eidus, Déborah Heintze, Dr. Antonio Sorrentino, Andrew Jackson, Katy McGirr, Laurent Audoly, Vivian Choi, Tirtha Chakraborty, Sashka Dimitrievska, Gregory Fiore, Marco Gottardis, Vijay Kasturi, Karuppiah Kannan, Johanna Kaufmann, PhD, Geoffrey Hodge, Jeffrey Humphrey, Mr. Punit Upadhyaya, Oscar Segurado, David Sherris, Reshma Singh, George Tetz

See the complete agenda and facilitator line-up

Download the strategy meeting brochure for full details

DOWNLOAD BROCHURE

Who Should Attend the Event?

Chief Executive Officers

Executive Vice Presidents

Vice Presidents

Executive Directors

Directors

Global Heads

Responsible For:

Oncology

Precision Medicine

Biomarker Discovery

Immuno-oncology

Clinical Research and Development

See Which Topics Are Discussed at the Strategy Meeting

09:00 – 10:00

Roundtable Tracks

Overcoming challenges for early phase I/O clinical trials and maximizing opportunities for biomarker discovery

Translating cancer ‘omics’ to improved outcomes

What is the next generation of ADC’s?

Radioactivity – A particularly sensitive “antenna” with excellent tissue penetration

Role of machine learning in clinical research: transforming the future of evidence generation

Cell and Gene Therapy landscape in Hematological malignancies: Next-generation innovations beyond traditional Lentiviral CAR-T

10:00 – 10:10

11:10 – 12:00

Roundtable Tracks

Autoantibody biomarkers for patient stratification: An approach to trial enrichment & drug repurposing SENGENICS

Funding early biotech companies in the Biden administration era with an emphasis on oncology FOR SPONSOR

Tissue Biomarkers Innovations in Immuno-Oncology LUNAPHORE

Reasons To Attend the Strategy Meeting

Evaluating current industry best practices to merge biomarkers for individual profiling

Getting a better understanding of the next-gen antibodies and clinical trials in oncology

Leveraging the role of ctDNA genotyping to monitor minimal residual disease

Tap into the full potential of NK cells and cell/gene therapy as novels modalities

Press play to hear what your colleagues had to say...

Become an official strategy meeting partner

Whatever your business needs, we can help. Get in touch for partnering opportunities

I’D LIKE TO PARTNER

Here To Help

Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.

Quick Links

Want to find out more?

Find out more details about our Strategy Meetings and other news and events.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Boston

Medicinal Chemistry Strategy Meeting East Coast – Boston 2024

Oncology

Strategy Meeting East Coast USA 2022

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Le Meridien Cambridge Boston

Fresh Oncology Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Meet Our 2022 Facilitators

Claudia Hesselmann, PhD

Tatiana Eidus

Déborah Heintze

Dr. Antonio Sorrentino

Andrew Jackson

Katy McGirr

Laurent Audoly

Vivian Choi

Tirtha Chakraborty

Sashka Dimitrievska

Gregory Fiore

Marco Gottardis

Vijay Kasturi

Karuppiah Kannan

Johanna Kaufmann, PhD

Geoffrey Hodge

Jeffrey Humphrey

Mr. Punit Upadhyaya

Oscar Segurado

David Sherris

Reshma Singh

George Tetz

See the complete agenda and facilitator line-up

Who Should Attend the Event?

Chief Executive Officers

Executive Vice Presidents

Vice Presidents

Executive Directors

Directors

Global Heads

Responsible For:

Oncology

Precision Medicine

Biomarker Discovery

Immuno-oncology

Clinical Research and Development

See Which Topics Are Discussed at the Strategy Meeting

REGISTRATION AND WELCOME

OPENING KEYNOTE PRESENTATIONDrugging the Tumor Microenvironment to achieve durable response in patients

Roundtable

Roundtable Tracks

Overcoming challenges for early phase I/O clinical trials and maximizing opportunities for biomarker discovery

Translating cancer ‘omics’ to improved outcomes

What is the next generation of ADC’s?

Radioactivity – A particularly sensitive “antenna” with excellent tissue penetration

Role of machine learning in clinical research: transforming the future of evidence generation

Cell and Gene Therapy landscape in Hematological malignancies: Next-generation innovations beyond traditional Lentiviral CAR-T

REFRESHMENT BREAK

NETWORKING / 1-1 MEETINGS

NETWORKING / 1-1 MEETINGS

NETWORKING / 1-1 MEETINGS

Roundtable

Roundtable Tracks

Autoantibody biomarkers for patient stratification: An approach to trial enrichment & drug repurposing SENGENICS

Funding early biotech companies in the Biden administration era with an emphasis on oncology FOR SPONSOR

Tissue Biomarkers Innovations in Immuno-Oncology LUNAPHORE

LUNCH BREAK

Reasons To Attend the Strategy Meeting

Our 2022 Lead Sponsor

Press play to hear what your colleagues had to say...

Le Meridien Cambridge Boston

OPENING KEYNOTE PRESENTATION
Drugging the Tumor Microenvironment to achieve durable response in patients